MetLife Investment Management LLC Grows Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

MetLife Investment Management LLC grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 84,360 shares of the biopharmaceutical company’s stock after purchasing an additional 3,752 shares during the quarter. MetLife Investment Management LLC’s holdings in TG Therapeutics were worth $2,539,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Barclays PLC raised its holdings in shares of TG Therapeutics by 83.9% in the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after buying an additional 158,323 shares during the last quarter. Synovus Financial Corp purchased a new position in shares of TG Therapeutics in the third quarter worth about $465,000. Franklin Resources Inc. lifted its holdings in shares of TG Therapeutics by 3.8% during the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock worth $2,945,000 after purchasing an additional 4,756 shares during the period. Principal Financial Group Inc. boosted its position in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after buying an additional 725,371 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after buying an additional 270,286 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $41.33 on Monday. The company has a market capitalization of $6.56 billion, a PE ratio of -413.26 and a beta of 2.14. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company’s fifty day moving average price is $37.18 and its 200 day moving average price is $32.59. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

TGTX has been the subject of several research reports. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.